GleamWall
中文EN

ABPO Abpro Holdings, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1893219 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY119.1%
TTM EPS YoY108.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR-26.1%

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA46.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets156.9%
Debt / equity—
Current ratio0.62x
Interest coverage-22.07x

Cash quality & payout

Operating cash flow / net income-3.00x
Accruals ratio184.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue—$183,000
R&D expense$989,000$2.98M
SG&A expense$7.46M$7.12M
Operating income-$8.45M-$9.92M
Interest expense$1.13M$387,000
Pretax income—-$7.23M
Net income-$2.89M-$7.23M
EBITDA-$8.43M-$9.85M
EPS (basic)-1.30-22.31
EPS (diluted)-1.30-22.31
Weighted avg. shares (diluted)2.23M780,332
Balance sheet
Cash & equivalents$82,000$2.99M
Receivables$183,000$183,000
Current assets$896,000$3.78M
PP&E, net—$37,000
Total assets$1.06M$4.66M
Current liabilities$9.35M$19.61M
Total liabilities$9.35M$19.61M
Shareholders' equity-$8.83M-$15.49M
Shares outstanding2.73M1.69M
Cash flow statement
Operating cash flow-$6.01M-$9.03M
Financing cash flow$3.07M$11.16M
Depreciation & amortization$21,000$74,000
Stock-based compensation$1.49M$1.93M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.